Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433158 · ClinicalTrials.gov registry record · Phase 3
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
A Phase 3 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT02433158: Clinical Trial Phase 3 study, sponsored by GlycoMimetics Incorporated.
NCT02433158 is a Phase 3 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 154 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02433158, a Phase 3 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
Primary Outcome
Number (%) of subjects with treatment emergent adverse events (TEAEs) over the study, number of TEAEs over the study and rate of TEAEs per subject per Vaso-Occlusive Crisis (VOC) will be summarized overall, by system organ class and by preferred term.
Interventions
- DRUG Rivipansel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 3 |
Why NCT02433158 stopped before completion
NCT02433158 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Rivipansel is the first listed.
NCT02433158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02433158 about?
NCT02433158 is a clinical study titled "Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease". This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
What is the current status of trial NCT02433158?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2015-12-16. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT02433158?
The interventions under investigation include: Rivipansel (DRUG).
Who is sponsoring clinical trial NCT02433158?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02433158's enrollment target sits among peer trials
154 1509th of 2000 higher than 491 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI